Full clinical comparison

Semaglutide vs Tirzepatide
vs Retatrutide

Every GLP-1 class fat loss compound compared side by side — clinical weight loss data, mechanism differences, titration protocols, and which one is right for your goals.

CompoundMechanismPeak Weight LossTrial DataHalf-LifeDifficulty

Semaglutide

Single

GLP-1 agonist14.9%

body weight

STEP 1 (68 wk)7 daysBeginner

Tirzepatide

Dual

GLP-1 + GIP agonist22.5%

body weight

SURMOUNT-1 (72 wk)5 daysIntermediate

Retatrutide

Triple

GLP-1 + GIP + GCG agonist24%+

body weight

Phase 2 TRIUMPH (24 wk)~7 daysAdvanced

CagriSema

Dual (GLP-1 + amylin)

GLP-1 + amylin agonist~15.6%

body weight

REDEFINE (Phase 2)7 days (both)Intermediate

Why agonism count matters

Each additional receptor agonism adds an independent appetite and metabolic mechanism. More pathways means more total effect — but also more complexity and side effect burden.

GLP-1 receptor

Slows gastric emptying, signals satiety to the brain, stimulates insulin release

Active in: All four compounds

GIP receptor

Adds a second satiety pathway; enhances insulin response; appears to amplify GLP-1 effects rather than simply duplicate them

Active in: Tirzepatide, Retatrutide

Glucagon receptor

Raises basal metabolic rate via thermogenesis (~5–8% BMR increase); drives hepatic fat mobilization and liver fat reduction

Active in: Retatrutide only

SingleBeginner

Semaglutide

GLP-1 agonist

Peak weight loss

14.9%

Trial

STEP 1 (68 wk)

Half-life

7 days

Start dose

0.25mg/week

Most data — longest human use record

Simplest titration schedule

Well-understood side effect profile

Best starting point for GLP-1 beginners

Lower weight loss ceiling vs dual/triple agonists

No GIP or glucagon pathway activation

DualIntermediate

Tirzepatide

GLP-1 + GIP agonist

Peak weight loss

22.5%

Trial

SURMOUNT-1 (72 wk)

Half-life

5 days

Start dose

2.5mg/week

22.5% mean weight loss — best of any approved drug at launch

GIP activation adds a second appetite suppression pathway

Better metabolic markers (HbA1c, insulin sensitivity)

Weekly injection — same convenience as semaglutide

More complex titration than semaglutide

Slightly higher GI burden at equivalent doses

TripleAdvanced

Retatrutide

GLP-1 + GIP + GCG agonist

Peak weight loss

24%+

Trial

Phase 2 TRIUMPH (24 wk)

Half-life

~7 days

Start dose

0.5–1mg/week

Highest weight loss in class — glucagon adds thermogenesis

Raises basal metabolic rate (~5–8%) via glucagon receptor

50–60% liver fat reduction (TRIUMPH data)

Three independent mechanisms working simultaneously

Phase 3 only — not yet an approved pharmaceutical

Most complex titration; highest GI side effect burden

Not appropriate for beginners

Dual (GLP-1 + amylin)Intermediate

CagriSema

GLP-1 + amylin agonist

Peak weight loss

~15.6%

Trial

REDEFINE (Phase 2)

Half-life

7 days (both)

Start dose

0.16mg cagri + 0.25mg sema

Amylin pathway is completely distinct from GLP-1/GIP

Combined weekly injection for both components

Unique postprandial glucose and gastric emptying effects

Suitable for GLP-1 responders wanting a second mechanism

Weight loss similar to semaglutide alone — amylin adds modest incremental benefit

Requires titrating two compounds independently

Want the full clinical breakdown of every GLP-1 compound?

Full Fat Loss Peptide Guide